Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bridgebio Pharma Inc
(NQ:
BBIO
)
26.19
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bridgebio Pharma Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Looking Into BridgeBio Pharma's Return On Capital Employed
November 23, 2022
Via
Benzinga
BridgeBio Pharma to Participate in November Investor Events
November 09, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma: Q3 Earnings Insights
November 03, 2022
BridgeBio Pharma (NASDAQ:BBIO) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement.
Via
Benzinga
BridgeBio Pharma, Inc. Reports Third Quarter 2022 Financial Results and Business Update
November 03, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Highlights its RAS Precision Oncology Portfolio and Shares Compelling Data from Next-generation G12C Inhibitor and Novel PI3Kα:RAS Breaker Mechanism at the Fourth RAS Initiative Symposium
October 17, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Shares Preliminary Data From Gene Therapy Candidate In Ultra Rare Disorder
October 14, 2022
Via
Benzinga
LianBio To Shut BridgeBio-Partnered Bile Duct Cancer Drug Trial
October 13, 2022
Via
Benzinga
BridgeBio Pharma Presents 12-month Results from Phase 2 Study of BBP-418 in Limb-Girdle Muscular Dystrophy Type 2i (LGMD2i)
October 14, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society
October 13, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Announces First Lung Cancer Patient Dosed in Phase 1/2 Trial and US FDA Fast Track Designation for SHP2 inhibitor BBP-398 in Combination with Amgen’s LUMAKRAS® (sotorasib)
October 11, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Starts Dosing In Early-Stage Genetic Metabolism Disorder Trial
August 18, 2022
Via
Benzinga
BridgeBio Pharma Touts Encouraging Data From Dwarfism Candidate
July 26, 2022
Via
Benzinga
BridgeBio Pharma to Present New Data on its Novel Approaches to RAS-driven Cancers at the Fourth RAS Initiative Symposium
October 07, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
September 14, 2022
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...
Via
Benzinga
BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease
June 22, 2022
Via
Benzinga
BridgeBio Pharma Posts Early Data From Neurological Movement Disorder Candidate
May 26, 2022
Via
Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
September 13, 2022
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.
Via
Benzinga
BridgeBio Pharma Earnings Perspective: Return On Capital Employed
August 25, 2022
According to Benzinga Pro data, during Q2, BridgeBio Pharma (NASDAQ:BBIO) posted sales of $73.75 million. Earnings were up 98.73%, but BridgeBio Pharma still reported an overall loss of $2.56 million.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
August 25, 2022
Via
Benzinga
Recap Of Thursday's Biotech Catalysts - End Of the Day Summary
August 18, 2022
Via
Benzinga
BridgeBio Shares Fall As Initial-Stage Rare Metabolic Disorder Study Kicks-off
August 18, 2022
BridgeBio Pharma (NASDAQ: BBIO) has dosed first patient in its Phase 1 clinical trial of BBP-671, an investigational oral therapy being developed for the potential treatment of conditions caused by...
Via
Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
August 10, 2022
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
August 03, 2022
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
July 26, 2022
Via
Benzinga
Why This Biotechnology Surged More Than 60%; Here Are 67 Biggest Movers From Yesterday
July 27, 2022
Gainers Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA) shares surged 94.3% to close at $1.69 on Tuesday after the company filed a request for the withdrawal of the Registration Statement on Form S-1.
Via
Benzinga
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
July 26, 2022
From
BridgeBio Pharma, Inc.
Via
GlobeNewswire
BridgeBio Pharma Reveals Early Positive Data For Canavan Disease
June 22, 2022
BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.
Via
Benzinga
89 Biggest Movers From Friday
June 21, 2022
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 bankruptcy.
Via
Benzinga
BridgeBio Pharma's Return On Capital Employed Insights
May 31, 2022
Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter.
Via
Benzinga
6 Analysts Have This to Say About BridgeBio Pharma
May 24, 2022
Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.